公开(公告)号：US20130115227A1

公开(公告)日：2013-05-09

申请号：US13809475

申请日：2011-07-13

申请人： Renee C. Gaspar ,  Paul J. Shughrue ,  Fubao Wang ,  Weirong Wang ,  Ningyan Zhang ,  Wei-Qin Zhao ,  Min Xu ,  Alexander McCampbell

发明人： Renee C. Gaspar ,  Paul J. Shughrue ,  Fubao Wang ,  Weirong Wang ,  Ningyan Zhang ,  Wei-Qin Zhao ,  Min Xu ,  Alexander McCampbell

IPC分类号： C07K16/18

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

摘要： Disclosed are antibodies that bind amyloid beta-derived diffusible ligands, also known as ADDLs. The antibodies are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.

摘要翻译： 公开了结合淀粉样蛋白β-衍生的扩散配体（也称为ADDL）的抗体。 抗体对ADDL是有选择性的，可以渗透大脑，并且可用于检测ADDLs和诊断阿尔茨海默氏病的方法。 抗体还阻断ADDL与神经元的结合，ADDLS的组装和tau磷酸化，并且在用于预防和治疗与ADDL相关的疾病的方法中是有用的。

公开(公告)号：US09176151B2

公开(公告)日：2015-11-03

申请号：US13544600

申请日：2012-07-09

申请人： William F. Goure ,  Renee C. Gaspar ,  Alexander McCampbell ,  Mary J. Savage ,  Paul J. Shughrue ,  Fubao Wang ,  Weirong Wang ,  Abigail L. Wolfe ,  Nigyan Zhang ,  Wei-Qin Zhao

发明人： William F. Goure ,  Renee C. Gaspar ,  Alexander McCampbell ,  Mary J. Savage ,  Paul J. Shughrue ,  Fubao Wang ,  Weirong Wang ,  Abigail L. Wolfe ,  Nigyan Zhang ,  Wei-Qin Zhao

IPC分类号： C07K16/18 ,  G01N33/532 ,  G01N33/68

CPC分类号： G01N33/6896 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N2333/4709 ,  G01N2800/2821

摘要： This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.

摘要翻译： 本发明是一种选择性的 低聚物试剂盒和免疫测定法，能够可靠而灵敏地检测A＆bgr; 患者生物样品中的低聚物。 在一个实施方案中，本发明的测定使用一对抗A＆bgr; 低聚物抗体作为捕获和检测抗体，用于检测和定量A＆bgr; 低聚物。 该方法可用于区分阿尔茨海默病（AD）患者和非AD患者和/或根据其疾病的严重程度分层AD患者。

公开(公告)号：US20130052670A1

公开(公告)日：2013-02-28

申请号：US13544554

申请日：2012-07-09

申请人： Mary Savage ,  Paul Shughrue ,  Abigail Wolfe ,  Alexander McCampbell

发明人： Mary Savage ,  Paul Shughrue ,  Abigail Wolfe ,  Alexander McCampbell

IPC分类号： G01N33/566 ,  G01N21/64

CPC分类号： G01N33/6896 ,  C07K16/18 ,  C07K2317/24 ,  G01N2800/2821 ,  G01N2800/52

摘要： The invention herein is directed to a selective Aβ oligomer immunoassay capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-AP oligomer antibodies, 19.3 and 82E1, to detect and quantify Aβ oligomers in a cerebrospinal fluid (CSF) sample. The inventive assay can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease. The inventive assay can also be used as a target engagement assay that can measure bound Aβ oligomers as a surrogate end-point for the assessment of therapeutic efficacy and/or target engagement.

摘要翻译： 本发明涉及一种选择性A＆Bgr; 低分子免疫测定能够可靠和敏感地检测A＆bgr; 患者生物样品中的低聚物。 在一个实施方案中，本发明的测定使用一对抗AP寡聚体抗体19.3和82E1来检测和定量A＆bgr; 脑脊液（CSF）样品中的低聚物。 本发明的测定可用于区分来自非AD患者的阿尔茨海默病（AD）患者和/或根据其疾病的严重程度分层AD患者。 本发明的测定法也可以用作可以测量结合的A和Bgr的目标接合测定; 寡聚体作为用于评估治疗功效和/或靶标参与的替代终点。